Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi.

J Med Chem 2017 09 27;60(17):7284-7299. Epub 2017 Aug 27.

Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee , Sir James Black Centre, Dundee DD1 5EH, U.K.

Chagas' disease, caused by the protozoan parasite Trypanosoma cruzi, is the most common cause of cardiac-related deaths in endemic regions of Latin America. There is an urgent need for new safer treatments because current standard therapeutic options, benznidazole and nifurtimox, have significant side effects and are only effective in the acute phase of the infection with limited efficacy in the chronic phase. Phenotypic high content screening against the intracellular parasite in infected VERO cells was used to identify a novel hit series of 5-amino-1,2,3-triazole-4-carboxamides (ATC). Optimization of the ATC series gave improvements in potency, aqueous solubility, and metabolic stability, which combined to give significant improvements in oral exposure. Mitigation of a potential Ames and hERG liability ultimately led to two promising compounds, one of which demonstrated significant suppression of parasite burden in a mouse model of Chagas' disease.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.7b00463DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601362PMC
September 2017
42 Reads

Publication Analysis

Top Keywords

trypanosoma cruzi
8
chagas' disease
8
efficacy chronic
4
mitigation potential
4
infection limited
4
limited efficacy
4
chronic phase
4
phase phenotypic
4
content screening
4
oral exposure
4
high content
4
phenotypic high
4
exposure mitigation
4
potential ames
4
herg liability
4
benznidazole nifurtimox
4
liability ultimately
4
options benznidazole
4
side effects
4
effects effective
4

Similar Publications